Solid Biosciences today announced preliminary findings from its IGNITE-DMD trial, which has so far tested SGT-001 in three boys. Muscle biopsies taken after three months showed low levels of micro-dystrophin protein. Although this is disappointing news, it’s important to remember that IGNITE-DMD is a dose-escalation study, and these three boys received the lowest planned dose. These results confirm that a higher dose of SGT-001 will need to be tested in future patients.
Beatriz Bustillo Ramirez